Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Income: 2019-2025

Historic Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$15.4 million.

  • Keros Therapeutics' Operating Income rose 73.77% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 121.36%. This contributed to the annual value of -$210.8 million for FY2024, which is 24.06% down from last year.
  • As of Q3 2025, Keros Therapeutics' Operating Income stood at -$15.4 million, which was up 61.36% from -$39.8 million recorded in Q2 2025.
  • Keros Therapeutics' Operating Income's 5-year high stood at $152.0 million during Q1 2025, with a 5-year trough of -$58.7 million in Q3 2024.
  • Moreover, its 3-year median value for Operating Income was -$43.3 million (2023), whereas its average is -$25.8 million.
  • Its Operating Income has fluctuated over the past 5 years, first slumped by 556.80% in 2022, then soared by 413.59% in 2025.
  • Over the past 5 years, Keros Therapeutics' Operating Income (Quarterly) stood at -$4.9 million in 2021, then tumbled by 556.80% to -$32.0 million in 2022, then slumped by 45.35% to -$46.5 million in 2023, then fell by 14.64% to -$53.3 million in 2024, then skyrocketed by 73.77% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q3 2025, -$39.8 million for Q2 2025, and $152.0 million during Q1 2025.